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Abstract
Background: Glioblastoma (GBM) is a poorly immunogenic neoplasm treated with focused radiation. Immunotherapy
has demonstrated synergistic survival effects with stereotactic radiosurgery (SRS) in murine GBM. GITR is a
co-stimulatory molecule expressed constitutively on regulatory T-cells and by effector T-cells upon activation.
We tested the hypothesis that anti-GITR monoclonal antibody (mAb) and SRS together would confer an
immune-mediated survival benefit in glioma using the orthotopic GL261 glioma model.
Methods: Mice received SRS and anti-GITR 10 days after implantation. The anti-GITR mAbs tested were formatted as
mouse IgG1 D265A (anti-GITR (1)) and IgG2a (anti-GITR (2a)) isotypes. Mice were randomized to four treatment groups:
(1) control; (2) SRS; (3) anti-GITR; (4) anti-GITR/SRS. SRS was delivered to the tumor in one fraction, and mice were
treated with mAb thrice. Mice were euthanized on day 21 to analyze the immunologic profile of tumor, spleen, and
tumor draining lymph nodes.
Results: Anti-GITR (1)/SRS significantly improved survival over either treatment alone (p < .0001) with a cure rate of
24 % versus 0 % in a T-lymphocyte-dependent manner. There was elevated intratumoral CD4+ effector cell infiltration
relative to Treg infiltration in mice treated with anti-GITR (1)/SRS, as well as significantly elevated IFNγ and IL-2
production by CD4+ T-cells and elevated IFNγ and TNFα production by CD8+ T-cells. There was increased mRNA
expression of M1 markers and decreased expression of M2 markers in tumor infiltrating mononuclear cells. The
anti-GITR (2a)/SRS combination did not improve survival, induce tumor regression, or result in Treg depletion.
Conclusions: These findings provide preclinical evidence for the use of anti-GITR (1) non-depleting antibodies in
combination with SRS in GBM.
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Background
Glioblastoma (GBM) is the most prevalent primary brain
tumor in adults, with a bleak median survival of 1–2
years and a <10 % 5-year survival rate [1–3]. The current
standard of care for GBM includes surgical resection,
temozolomide chemotherapy, and radiation for recur-
rence, but with only modest improvements in survival
the search has intensified for more effective therapies
[4]. Preclinical studies have demonstrated early successes
for the use of immunotherapy against glioma, including
antibody-mediated blockade of checkpoints including
anti-programmed death-1 (anti-PD-1), anti-cytotoxic T
lymphocyte antigen-4 (anti-CTLA-4), and anti-4-1BB,
particularly in combination with radiotherapy [5, 6]. As
a result, clinical trials are now underway testing check-
point inhibitors in human patients with GBM
(NCT02017717).
Glucocorticoid-induced tumor necrosis factor related
protein (GITR) is an immune checkpoint that belongs to
the tumor necrosis factor receptor (TNFR) family and is
expressed on T lymphocytes, natural killer cells, and
granulocytes [7]. The GITR ligand (GITR-L) is expressed
on antigen presenting cells (APCs) such as dendritic
cells, macrophages, and B-cells [8]. While expressed at
low basal levels in CD4+ and CD8+ effector T cells,
GITR is upregulated 24–72 h following an antigenic
stimulus and remains expressed at high levels for several
days [8, 9]. Conversely, GITR is constitutively expressed
in regulatory T cells (Tregs). It has been observed that
binding of GITR in CD4+ and CD8+ T cells by its ligand
results in increased effector function, cell proliferation,
and possible resistance to Treg immunosuppression,
whereas GITR stimulation in Tregs leads to FoxP3 loss,
Treg instability, and a decline in suppressive function
[10–12]. Anti-GITR monoclonal antibody (mAb) ther-
apy has resulted in tumor regression in a number of
tumor models, but has not yet been tested against mur-
ine glioma [12–17]. Similar to blockade of checkpoints
PD-1 and lymphocyte activating gene (LAG)-3, among
others, activation of TNFR family checkpoint molecules
has not led to severe toxicities in preclinical models,
making GITR an attractive target for future immune
checkpoint modulation [18, 19].
Cells damaged by ionizing radiation up-regulate pro-
inflammatory ligands and release cytokines and anti-
gens that become immunogenic substrates for
infiltrating immune cell activation [20, 21]. Stereotac-
tic radiosurgery (SRS) has the advantage of delivering
a high dose of radiation to the target while minimizing
damage to surrounding tissues. Commonly used in the
treatment of brain cancer, SRS can be an effective
measure to treat microscopic residual disease and
delay recurrence [22]. Studies of focal radiation in
combination with checkpoint modulation in preclinical
glioma and breast cancer models have exhibited favor-
able immune-mediated anti-tumor responses, and
phase I/II clinical studies of radiation therapy com-
bined with CTLA-4 blockade in prostate cancer have
yielded encouraging outcomes [5, 6, 23, 24]. Here, we
tested an anti-GITR IgG1 D265A (anti-GITR (1))
agonist and an anti-GITR IgG2a (anti-GITR (2a)) de-
pleting mAb in combination with SRS in a murine
intracranial glioma model. We found that anti-GITR
(1)/SRS significantly improves survival and delays
tumor progression in a CD4+ T cell dependent fashion
that involves intratumoral M1 macrophage polarization,
whereas anti-GITR (2a)/SRS does not prolong survival or
delay tumor progression.
Results
GITR activation and stereotactic radiosurgery together
produced long-term survivors and tumor regression in
murine intracranial GL261
To determine the effectiveness of GITR activation in
the setting of adjuvant focal radiation against estab-
lished GL261-luc murine glioblastoma tumors, an
anti-GITR (1) agonist mAb was dosed according to
previous studies of anti-GITR (1) in mouse tumor
models and combined with stereotactic radiosurgery
(SRS) dosed in a single fraction (Fig. 1a). SRS was
dosed prior to anti-GITR in order to create an inflam-
matory tumor microenvironment favorable to immune
modulation. Timing of SRS and anti-GITR dosage was
based upon previously established schedules that cor-
relate with tumor growth characteristics. Notably,
anti-GITR (1) mAb was engineered as an IgG1 isotype
with a D265A mutation that is unable to bind to Fc re-
ceptors; thus, anti-GITR (1) may only mediate bivalent
agonism of GITR without concern for target cell de-
pletion via antibody-dependent cell-mediated cytotox-
icity (ADCC). Our results indicate that GITR
activation alone did not inhibit tumor growth and re-
sulted in survival outcomes not statistically different
from controls (median survival anti-GITR (1) vs. con-
trol, 23 vs. 28 days) (Fig. 1b-c). Consistent with previ-
ous findings, SRS alone produced only partial tumor
regression and no long-term survivors (median sur-
vival: 28 days) (Fig. 1b-c). By contrast, the combin-
ation of anti-GITR (1) mAb and SRS synergized to
cure a subset of mice and produce a long-term sur-
vivor rate of 24 % (P < .0001, median survival: 31 days)
(Fig. 1b-c). To examine whether there were differences
in the intratumoral lymphocytic phenotype between
treatment groups that could account for differences in
survival, tumor-infiltrating lymphocytes (TIL) were
isolated from each group on day 21 and analyzed for
various T cell populations. While the proportion of
CD8+ and CD4+ TIL were elevated in the
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combination anti-GITR (1)/SRS group relative to the
negative control, this result was not statistically sig-
nificant. Moreover, the ratio of CD8+ to CD4+ T cells
was not significantly different between groups (data
not shown). The proportion of CD4 + FoxP3 + CD25hi
regulatory T cells (Treg) was similar between the com-
bination treatment group and control, but was signifi-
cantly elevated in mice that received only SRS. In all,
anti-GITR (1)/SRS combination therapy induced re-
gression of GL261 tumors and produced a subset of
cured long-term survivors in a manner that did not
alter the overall proportion of TIL populations com-
pared to controls.
The survival advantage conferred by anti-GITR (1)/SRS
combination therapy is dependent upon CD4+ cells and
may be dependent upon CD8+ cells
Immune subset analysis of TIL did not suggest statisti-
cally appreciable differences in the combination treat-
ment group relative to the control. As such, T cell subset
depletion studies were utilized to elucidate whether the
mechanism of anti-tumor effect of combination treat-
ment was dependent on a particular T cell population.
Systemic antibody-mediated CD4+ T cell depletion abro-
gated the survival benefit conferred by anti-GITR (1)/
SRS treatment, with a reduction in median survival of
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Fig. 1 Eradication of intracranial GL261 tumors with anti-GITR (1) mAb plus SRS combination therapy. C57/BL6 mice were intracranially inoculated
with 1.3 × 105 GL261-luc cells, and after tumor establishment was confirmed by bioluminescence, mice were randomized into four groups of 10
mice per arm on day 7. Mice were administered focal radiation of 10 Gy 10 days after tumor implantation and/or received 200 μl anti-GITR (1)
(10 mg/kg) by i.p. injection on days 10, 13, and 16 a. Mice were followed for survival b; curve-adjacent asterisks compare indicated curve to
control. Tumor size was followed with bioluminescent imaging c; four representative mice are shown. Mice were sacrificed on day 21, and tumor
infiltrating CD4 and CD8 T cells (gated on CD3+ cells) and Tregs (gated on CD4+ cells) were isolated and analyzed by flow cytometry d and e.
Symbol and horizontal bar (e) denote single mouse and average value, respectively. *P < .05, **P < .01, ****P < .0001
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vs. non-depleted, P < .01) (Fig. 2a). Of note, CD4+ deple-
tion in control mice did not alter the rate of tumor pro-
gression relative to non-depleted control mice (data not
shown). Systemic antibody-mediated CD8+ depletion re-
sulted in eventual death of all depleted mice. However,
CD8+ depletion did not abrogate the combination
treatment-induced survival benefit, as demonstrated by a
non-significant difference in median survival of CD8+
depleted mice compared to non-depleted mice, both
treated with anti-GITR (1)/SRS (median survival 28 vs.
30 days, P > .05) (Fig. 2b). These data signify that while
CD8+ T cells may not be integral to the combination
treatment mechanism, the lack of long-term survivors in
the CD8-depleted arm indicates that CD8+ cells are
likely involved in the anti-tumor treatment effect.
To further explore which CD4+ T cell subset may have
mediated the observed treatment effect, systemic deple-
tion of FoxP3+ Tregs was achieved with the use of
FoxP3DTR transgenic mice and diphtheria toxin. These
mice selectively express the diphtheria toxin receptor in
regulatory T cells. Mice with intracranial GL261 treated
with combination therapy exhibited similar tumor re-
gression 21 days after tumor implantation in the Treg
depleted and non-depleted groups (Fig. 2c-d). Our re-
sults indicate that depletion of FoxP3+ cells did not ab-
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Fig. 2 Survival benefit conferred by anti-GITR (1)/SRS treatment of murine glioma requires CD4+ T cells. C57/BL6 mice were inoculated with
intracranial GL261-luc tumor, randomized to ≥7 mice per group and administered anti-GITR (1) and SRS as in Fig. 1. Mice were injected i.p. with
200 μl anti-CD4 (10 mg/kg) a and anti-CD8 (10 mg/kg) b depleting antibodies on days 5–7, 14, and 28 and followed for survival. Curve-adjacent
asterisks compare indicated curve to control. The same control, anti-GITR (1), and anti-GITR (1)/SRS groups were used in (a) and (b) as the experiments
were performed concurrently. The difference in survival between control mice and mice depleted of CD8+ T cells was statistically significant, but was
not significant in the absence of CD4+ cells. FoxP3DTR mice were inoculated intracranially with 1.3 × 105 GL261-luc cells, randomized, injected i.p. with
200 μl of diphtheria toxin (50 ng/g) on day 8, 9 and every 2 days thereafter in order to achieve FoxP3+ cell depletion, administered anti-GITR (1) or SRS
as in Fig. 1., and followed for tumor growth by bioluminescent imaging c. Tumor size was quantified by bioluminescence d. *P < .05; **P < .01.
NS, non-significant
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combination therapy as exhibited by bioluminescent im-
aging of the tumor. Together, these data suggest that the
anti-tumor effect conferred by anti-GITR (1)/SRS treat-
ment is dependent upon the CD4+ effector T cell popu-
lation, may be dependent upon CD8+ T lymphocytes,
and is not dependent upon FoxP3+ T cells.
CD4+ and CD8+ TIL have elevated cytokine production in
mice treated with anti-GITR (1)/SRS and a significantly
elevated CD4 + IFNγ+/Treg ratio
Given the apparent dependence of combination
treatment on CD4+ T cells and possible dependence on
CD8+ T cells, we sought to identify the effector lympho-
cyte phenotype potentially responsible for the treatment
mechanism. Phenotypic analysis of TIL revealed signifi-
cantly elevated percentage of CD4 + IFNγ + and CD8 +
IFNγ + cells, CD8 + TNFα + cells, and CD4 + IL-2+ cells
in mice treated with anti-GITR (1)/SRS relative to the
control (P < .05 for all) (Fig. 3a-b). There were no signifi-
cant differences in cytokine production between single-
treatment arms and control. There was elevated IL-2
production by CD8+ T cells in the combination treat-
ment group, but this result was not statistically signifi-
cant. Given that Tregs are a significant source of
immunosuppression in the tumor microenvironment,
and that the proportion of the Treg subset among TIL
in the combination treatment group was not diminished
relative to the control (Fig. 1c), we hypothesized that the
ratio of effector T cells to Tregs was elevated in the anti-
GITR (1)/SRS group relative to the control. Such a rela-
tive increase in the pro-inflammatory phenotype could
account for the ability of TIL receiving combination
treatment to overcome local immunosuppression. Sup-
porting this hypothesis, our results indicated a signifi-
cantly elevated CD4 + IFNγ + to Treg ratio in mice
receiving anti-GITR (1)/SRS relative to the control and
SRS alone groups (P < .05), and a trend toward increased
CD8 + IFNγ + to Treg ratio in the combination treat-
ment group (Fig. 3c). These findings suggest that both
CD4+ and CD8+ TIL may be involved in the anti-GITR
(1)/SRS treatment regimen.
Combination treatment yields intratumoral myeloid cells
with overall lower expression of M2 and higher
expression of M1 markers
Our data indicate that Th1-type CD4+ cells may be an
effector lymphocyte population in the combination treat-
ment regimen. Th1 immune cells are pro-inflammatory
and secrete IFNγ as their primary cytokine, among
others. Given that Th1 CD4+ T cells are known to pro-
vide key activating signals to myeloid lineage cells, we
hypothesized that the anti-GITR (1)/SRS treatment re-
sulted in downstream activation of intratumoral resident
and infiltrating myeloid-derived cells that ultimately
contributed to the anti-tumor effect. To test this hy-
pothesis, CD11b + CD45+ myeloid cells were isolated
from tumor and queried for mRNA expression of M1
and M2 genetic markers via quantitative reverse
transcriptase-PCR (Fig. 4, Additional file 1: Figure S1).
Macrophages exist on a phenotypic continuum from
the M1 (inflammatory and anti-tumorigenic) pheno-
type, to the M2 (regulatory and pro-tumorigenic)
phenotype [25]. This population included microglia as
well as tumor-infiltrating mononuclear cells. There
was increased expression in the combination treat-
ment group of M1 markers IL12 (vs. SRS alone, P
< .05; Fig. 4a) and MhcII (vs. SRS alone, P < .01; vs.
control P < .001; Fig. 4b). Expression of M1 marker
Inos was elevated in the combination treatment rela-
tive to SRS alone (P < .001) but was decreased relative
to control (P < .01) (Fig. 4d). The M1 marker Cd86
and M2 marker Cd163 were not significantly different
in the combination treatment group relative to SRS
only or control (Fig. 4b-c). There was decreased ex-
pression in the combination treatment group of M2
markers IL10 (vs. SRS alone, P < .05), Cd206 (vs. SRS
alone, P < .05; vs. control, P < .0001), and Arg1 (vs. SRS
alone, P < .05; vs. control, P < .001). Finally, expression
of Tgfb (P < .01) and Pdl1 (P < .01) was decreased in
the combination treatment group relative to the con-
trol, although there was significantly higher expression
of Pdl1 in the anti-GITR (1)/SRS group relative to SRS
alone (P < .05) (Fig. 4a-b). Taken together, these data sug-
gest that the combination treatment induces up-regulation
of genes involved in the pro-inflammatory M1 phenotype,
with the exception of iNOS, and down-regulation of the
phenotypically immunosuppressive M2 genes in resident
microglia and tumor-infiltrating myeloid cells.
The anti-GITR IgG 2a antibody/SRS combination does not
prolong survival, does not induce intracranial GL261
tumor regression, and does not result in reduction of
intracranial tumoral Tregs
Because Tregs constitutively express GITR, we sought to
test an anti-GITR antibody that induced cell death via
antibody-dependent cell mediated cytotoxicity (ADCC).
We predicted that the up-regulation of GITR on Tregs
would result in disproportionate depletion of Tregs rela-
tive to CD4+ and CD8+ T cells after treatment with the
anti-GITR IgG 2a (anti-GITR (2a)) mAb, as has been
observed in flank tumor models [26]. We hypothesized
that those mice treated with anti-GITR (2a) would ex-
hibit significant intracranial GL261 tumor regression
relative to controls as a result of reductions in intratu-
moral Treg numbers. To test this, a survival study iden-
tical to that in Fig. 1 was conducted using anti-GITR
(2a) in place of anti-GITR (1) (Fig. 5). Notably, the anti-
GITR (2a) mAb differs from anti-GITR (1) in the Fc
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region only. Surprisingly, anti-GITR (2a) in combination
with SRS did not provide significant survival benefit over
the control or either treatment alone (Fig. 5a). Indeed,
bioluminescent imaging of tumors at day 21 after im-
plantation revealed significant tumor growth in the
combination treatment group comparative to that of the
control group (Fig. 5b). In order to gain insight into the
inability of the anti-GITR (2a)/SRS to produce survival
benefit, TIL were analyzed at day 21 for the distribution
















































































































































































































































































































Fig. 3 Tumor infiltrating lymphocytes (TIL) in the anti-GITR (1)/SRS group have a Th1 immunophenotype and elevated effector to Treg ratio.
C57BL/6 mice were inoculated with GL261-luc tumor, randomized to groups of ≥5, and dosed with anti-GITR (1) and SRS as in Fig. 1. Mice were
sacrificed on day 21, tumor infiltrating lymphocytes were isolated, cells were stimulated with PMA/Ionomycin, fixed, and permeabilized for
staining of intracellular markers. a CD8+ and b CD4+ cell populations were analyzed by flow cytometry for expression of IFNγ, TNFα, and IL-2.
Intratumoral effector CD8+ and CD4+ to Treg ratios in the anti-GITR (1)/SRS group were calculated c. Symbol and horizontal bar denote single
mouse and average value, respectively. *P < .05
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GITR (2a) alone or in combination with SRS did not in-
duce significant intratumoral depletion of Tregs (Fig. 5c).
It is known that anti-GITR (2a) relies upon the presence
of activating Fcγ-receptors (FcγR) on antigen presenting
cells (APCs) to mediate cell depletion via ADCC [26].
As such, we hypothesized that activating FcγR may be
absent in the microglia, which are the resident APCs of
the brain. Myeloid cells were harvested from intracranial
GL261 tumors at day 21 and analyzed for expression of

























































































































































































































































































































































































Fig. 4 Anti-GITR (1)/SRS yields intratumoral myeloid cells with lower expression of M2 and higher expression of M1 markers. C57BL/6 mice were
inoculated with GL261-luc tumor, randomized to groups of ≥5, and dosed with anti-GITR (1) and SRS as in Fig. 1. Mice were sacrificed on day 21,
tumor infiltrating mononuclear cells were isolated, CD11b + CD45+ cells were sorted, and total RNA was isolated. Gene expression was calculated
using real-time quantitative PCR analysis with 18 s as the endogenous control. Column dot plots illustrate gene expression of a cytokines, b cell
surface molecules, c cell surface receptors, and d cellular enzymes in each treatment group. *P < .05, **P < .01, ***P < .001, ****P < .0001
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hypothesis, the data suggest that intratumoral CD11b +
CD45lo resident microglia express significantly lower
levels of activating FcγR relative to intratumoral
CD11b + CD45hi mononuclear cells, which may ac-
count for the inability of anti-GITR (2a) to induce
Treg depletion through ADCC in brain tumor.
The efficacy of anti-GITR (2a) in Treg depletion may
be greater in flank tumor models because of the in-
creased presence of activating FcγR on peripheral mono-
nuclear cells relative to microglia. We tested this
hypothesis by simultaneously treating mice implanted
with either intracranial or flank tumors with three doses
of anti-GITR (2a), then harvesting tumors for flow cyto-
metric analysis of Treg populations (Fig. 5e, f ). While
brain tumors treated with anti-GITR (2a) did not have
significantly lower levels of intratumoral CD4 + FoxP3+
cells relative to control, anti-GITR (2a) treatment in
flank tumors did result in a significantly diminished pro-
portion of CD4 + FoxP3+ relative to control (Fig. 5e, f ).
To summarize, these data signify that the anti-GITR
(2a) antibody in combination with SRS does not provide
a significant survival benefit in mice with intracranial
GL261 relative to the control and cannot mediate intra-
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Fig. 5 Lack of intracranial tumor eradication and Treg depletion with the anti-GITR IgG 2a antibody/SRS combination. C57BL/6 mice were intracranially
inoculated with GL261-luc tumor, randomized to groups of ≥8, and dosed with 200 μl of anti-GITR (2a) (10 mg/kg) on day 10, 13, 16 and/or SRS
(10 Gy) on day 10. Mice were followed for survival, a and tumor growth was assessed by bioluminescent imaging b. Mice were sacrificed on day 21,
tumor infiltrating Tregs were isolated and analyzed by flow cytometry c. CD11b + CD45+ tumor resident microglia and tumor infiltrating mononuclear
cells were isolated on day 21, analyzed by flow cytometry (gated on CD3+ cells), and mean fluorescence intensity (MFI) of FcγRIII and IV expression
was calculated d. Flank tumors were established in C57BL/6 mice by subcutaneous inoculation of 2 × 106 GL261-luc cells in a volume of 100 μl, and
intracranial tumors were established as in Fig. 1. Mice were dosed i.p with 200 μl of anti-GITR (2a) (10 mg/kg) on days 10, 13, and 16, sacrificed on day
17, and tumor infiltrating lymphocytes were harvested and analyzed by flow cytometry for FoxP3 expression (gated on CD3+ cells) e-f. Symbol and
horizontal bar denote single mouse and average value, respectively. *P < .05, ***P < .001. NS, non-significant
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Tregs, possibly owing to the relatively low expression of
activating FcγR on intratumoral microglia.
Discussion
The advent of immunotherapeutics has introduced new
and exciting opportunities for the treatment of a variety
of advanced cancers. It is important to bear in mind,
however, that brain tumors such as GBM pose dual ob-
stacles in the search for effective immunotherapies: low
immunogenicity and residence in the immunologically
distinct cranial vault [27]. In spite of this, pre-clinical
models have shown promising efficacy of checkpoint in-
hibitors against glioma, and clinical trials of checkpoint
blockade in human GBM are underway [5, 27].
Toxic side effects emerging from the blockade of the
first generation of immune checkpoint targets have en-
couraged study of other checkpoint molecules with less
severe autoimmune sequelae [28]. The TNFR family of
checkpoint molecules including GITR, 4-1BB and OX40
is an attractive target for immunotherapy because of the
relative lack of significant autoimmunity when stimu-
lated [18, 19]. Stimulation of TNFR checkpoints 4-1BB
and OX40 in pre-clinical glioma models has demon-
strated immune-mediated regression of tumors with low
resulting toxicity [5, 29, 30]. The effect of an anti-GITR
agonist in the setting of murine glioma has not been
investigated prior to this study, although GITR activa-
tion is an appealing strategy for its dual stimulatory
influence on effector T cells and suppressive effect on
Tregs [8, 10–13, 15, 17]. Here, we report that anti-
GITR IgG1 agonist mAb in combination with SRS
induces significant tumor regression and produces
long-term survivors in murine intracranial glioma.
These effects appear to be dependent upon CD4+ ef-
fector cells and may be dependent upon CD8+ cells.
Additionally, we report the lack of efficacy of an anti-
GITR IgG2a mAb alone or in combination with SRS
to produce tumor regression or long-term survival in
intracranial glioma, potentially owing to differences in
Fc receptor expression by CNS-resident APCs.
We observed that anti-GITR (1)/SRS therapy signifi-
cantly prolonged survival, whereas either therapy alone
did not provide any survival benefit (Fig. 1a-b). Radiation
has been shown to potentiate immune checkpoint block-
ade in intracranial and flank tumor models [5, 6, 23].
One hypothesis is that the damage of tumor cells pro-
duces an immunogenic substrate for infiltrating effector
lymphocytes through the release of antigens as well as
upregulation of cytokines and pro-inflammatory ligands
[31–35]. In our experiments, however, initial TIL ana-
lysis did not demonstrate appreciable differences in the
Treg or CD4+ and CD8+ populations between treatment
groups (Fig. 1c). Indeed, our results support the hypoth-
esis that the anti-tumor effect is more dependent upon
differences in cytokine secretion between CD4+ and
CD8+ cells rather than relative differences in tumor-
infiltrating lymphocyte density (Fig. 3). Previous studies
of anti-GITR treatment in flank tumor models have
shown decreased intratumoral Treg infiltrate and ele-
vated CD8+ relative to CD4 + Foxp3+ TIL, while studies
of intracranial glioma treated with focal radiation with
or without TNFR checkpoint stimulation also demon-
strated elevated levels of CD4+ and CD8+ TIL [5, 6, 12,
14]. It is important to note that studies of anti-GITR in
tumor models vary in the isotype of anti-GITR mAb
used—those that treat with a rat IgG2b mAb would ex-
pect to see some T cell depletion as they share the iso-
type with a number of in vivo depleting mAbs (i.e.,
GK1.5, YTS191, YTS169, etc.), and those testing an anti-
GITR mouse IgG2a should expect to see ADCC pathway
cell depletion mediated by FcγR interactions [14, 26].
Our use of a mouse IgG1 anti-GITR mAb may explain
the lack of reduction in CD4 + FoxP3+ cells, but does
not necessarily account for the lack of elevated CD4+
and CD8+ effector cell infiltration.
Nevertheless, our results suggest that the combination
treatment mechanism is dependent upon CD4+ non-
Treg cells and may have some dependence upon CD8+
cells (Fig. 2). While the treatment mechanism was en-
tirely abolished after depletion of CD4+ cells, anti-GITR
(1)/SRS treatment after CD8+ cell depletion did not pro-
duce long-term survivors, but also did not significantly
reduce median survival compared to non-depleted mice
(Fig. 2a-b). Our results align with previous studies of
TNFR checkpoint stimulation in combination with SRS
in intracranial glioma, which indicated that CD4+ deple-
tion abrogated treatment effect while CD8+ depletion
did not [5]. While studies of anti-GITR in flank melan-
oma models have demonstrated CD8+ mechanistic dom-
inance, more recent studies in flank tumor have
emphasized the importance of CD4+ helper-T cells in
coordinating a CD8+ anti-tumor response [12, 13, 36].
The difference in T cell subset dominance between stud-
ies in melanoma and our findings may be rooted in the
immunologic distinctiveness of the tumor microenviron-
ment in flank versus intracranial tumor models [27, 37].
In support of Th1-type CD4+ T cell involvement in
our combination treatment mechanism, we observed a
significantly elevated CD4 + IFNγ + to Treg ratio in our
combination treatment group, as well as elevated CD4+
production of IFNγ and IL-2 and CD8+ production of
IFNγ and TNFα (Fig. 3). Corroborating our observations
in Fig. 2, while the CD8 + IFNγ + to Treg ratio was ele-
vated in our combination treatment relative to control,
the difference was not statistically significant (Fig. 3c).
Together, these data suggest a possible involvement of
CD8+ T cells in the anti-tumor response. While our re-
sults supported previous findings of the increase in
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intratumoral multifunctional CD8+ T cells after GITR
stimulation, others observed significantly elevated CD8+
effector to Treg ratios and direct co-stimulatory effects
on CD8+ cells [12, 13, 38]. Further investigation in the
intracranial glioma model is necessary to more defini-
tively ascertain the role of CD8+ cells in the anti-GITR
(1)/SRS treatment effect. Moreover, of importance for
future study is the combination of SRS with Treg deple-
tion. Our results demonstrated elevated Treg levels in
the presence of SRS alone (Fig. 1e), as well as mildly ele-
vated IFNγ + effector T cells (Fig. 3). Future investigation
may involve augmentation of anti-tumor effect with the
combination of focal radiation and Treg depletion.
As CD4+ effector cells are not commonly the cyto-
toxic effector cells in an immune response, we hypothe-
sized that the combination treatment induced M1
polarization of mononuclear cells in the tumor micro-
environment, potentially recruited by IFNγ-secreting
CD4+ cells. Macrophages may be roughly categorized
as either M1 or M2 based on their overall gene expres-
sion pattern, but this distinction is not absolute as mac-
rophages may lie on a phenotypic spectrum [25].
Macrophages that are M1 are ‘classically activated’ and
anti-tumorigenic, whereas M2 macrophages are ‘alter-
natively activated,’ pro-tumorigenic, and are associated
with poor immune responses. With the exception of
Inos, we observed significantly elevated expression of
select stereotypically M1 genes and decreased expres-
sion of M2 genes in intratumoral CD11b + CD45+
mononuclear cells in the combination treatment group,
as well as decreased expression of Pdl1 and Tgfb
(Fig. 4). Cytokines released by local T cells are known
to influence macrophage polarization, with elevated
IFNγ release by Th1 cells promoting an M1 phenotype
[25, 39]. Indeed, our results indicate a significantly in-
creased proportion of CD4 + IFNγ + cells in the pres-
ence of anti-GITR (1)/SRS treatment, which may in
turn favor macrophage M1 polarization. We predict
that CD4+ Th1 cells may be dominant in the anti-
GITR (1)/SRS treatment mechanism because of their
integral role in macrophage polarization toward an M1
phenotype in the tumor microenvironment. A previous
study in murine ovarian cancer treated with PD-1
blockade combined with GITR stimulation showed a
significant decline in myeloid derived suppressor cells
(MDSCs) [16]. Our results corroborate the observation
of a decline in suppressive myeloid type cells after anti-
GITR treatment.
Finally, we present novel data that anti-GITR IgG2a
mAb alone or in combination with SRS does not medi-
ate a survival advantage and is not capable of depleting
Tregs in intracranial tumor (Fig. 5a–c). Anti-GITR (2a)
relies upon activating FcγR engagement to mediate cell
death of GITR-expressing cells via ADCC [26]. Because
regulatory T cells express constitutively high levels of
GITR, they are the primary cell population targeted for
cell death in the presence of anti-GITR (2a). It is import-
ant to note that in order for ADCC to occur, antigen
presenting cells (APCs) must be present that express the
appropriate Fc receptor specific to the antibody of inter-
est. Systemic tumor models treated with anti-GITR (2a)
undergo significant regression as well as depletion of
Tregs in a mechanism dependent upon activating FcγR,
including receptor variants III and IV [26]. We illustrate
that the primary APCs of the brain, the microglia, ex-
press significantly decreased levels of FcγRIII and IV
relative to macrophages infiltrating from the periphery
(Fig. 5d). Moreover, anti-GITR (2a) treatment resulted in
significant Treg depletion in flank GL261 tumors, sug-
gesting that factors unique to the intracranial compart-
ment are responsible for the lack of anti-GITR (2a)
mediated Treg depletion in brain tumor. These data may
provide a partial explanation for the lack of tumoral
Treg depletion and absence of survival benefit in our
intracranial glioma model after treatment with anti-
GITR (2a)/SRS, despite previous observations of sys-
temic tumor regression after anti-GITR (2a) treatment
[26]. We assume that microglia are the primary profes-
sional APCs of the CNS, and that their expression of
FcγR would be of greatest importance in evaluating the
effect of anti-GITR (2a)-mediated ADCC. While infil-
trating peripheral mononuclear cells may play a role in
FcγR-mediated ADCC in the presence of anti-GITR (2a),
this question is multidimensional and requires further
investigation. Namely, in addition to an enumeration of
intratumoral infiltrating mononuclear cells, the timing of
infiltration relative to antibody administration, as well as
the spatial distribution within the tumor architecture is
of great importance.
Nevertheless, our findings imply that depleting anti-
bodies dependent upon FcγR interactions, such as anti-
CTLA-4 or anti-OX40, may not be of clinical value in
brain cancer if the appropriate FcγR are also absent from
human microglia [40, 41]. Additional studies in humans
are necessary to confirm this hypothesis.
Conclusions
Together, these preclinical findings provide a strong ra-
tionale for the clinical testing of anti-GITR (1) and adju-
vant focal radiation combination therapy in the setting
of human GBM. The clinical translation of these therap-
ies to the clinic would be facile, given that a human
anti-GITR antibody is available (MK-4166) and SRS is
part of GBM standard of care. Data regarding immuno-
logic mechanisms we have presented here may serve as
a context for investigating biomarkers in future clinical
trials.
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Methods
Mice, reagents, and antibodies
Female C57BL/6 mice (The Jackson Laboratory) and
FoxP3DTR C57BL/6 (provided by Alexander Rudensky at
Memorial Sloan Kettering Cancer Center) mice (6–8
weeks) were housed in facilities in accordance with pro-
tocols approved by the Institutional Animal Care and
Use Committee of Johns Hopkins University. Anti-GITR
IgG1 D265A and IgG2a (Clone mGITR.7-mg2a) anti-
bodies were provided by Bristol-Myers Squibb Company,
and purified anti-CD4 (Clone GK1.5) and anti-CD8
(Clone 53–6.7) antibodies were purchased from BioXcell
(Cat. BE0003-1 and BE0004-1, respectively). Anti-GITR,
anti-CD4, and anti-CD8 antibodies were all diluted to
1 mg/kg and stored at 4 °C. Diphtheria toxin was pur-
chased from Sigma (Cat. D0564-1MG), diluted to a con-
centration of 5 μg/mL, and stored in 1 mL single-use
aliquots at−80 °C. GL261-luc is a mouse-derived glioma
cell line purchased from Caliper, and grown in DMEM
(Thermo Fisher Scientific) supplemented with 10 % fetal
bovine serum, 100 units/mL penicillin, 100 μg/mL
streptomycin, and 100 μg/mL G418 for selection. This
cell line was confirmed to be mycoplasma free using the
MycoDtect kit (Greiner Bio-One) performed at the
Fragment Analysis Facility at our institution.
Tumor establishment and antibody treatment
GL261-luc cells were maintained in cell culture in se-
lection media. Cells were grown to log phase, har-
vested, washed thoroughly three times in PBS,
counted, and brought to the appropriate concentration
in PBS. Cells were resuspended at 130,000 cells/μL for
intracranial implantation and at 20,000 cells/μL for
flank implantation.
Establishment of intracranial tumors was achieved as
previously described [6]. Briefly, mice were anesthetized
with 200 μl of ketamine (5 mg/mL)/xylazine (0.5 mg/mL)
in PBS and their heads were shaved, cleaned with
povidone-iodine, and incised at midline. A burr hole
1 mm in diameter was placed over the left hemisphere
2 mm posterior to the coronal suture and 2 mm lateral to
the sagittal suture. After positioning mice in a stereotactic
frame, the needle was advanced 3 mm below the dura.
Tumor cells were injected in a volume of 1 μL over 1 min.
The skin was closed with staples. Flank tumors were
established by subcutaneous injection of the tumor cell
suspension in a volume of 100 μL into the left flank. Intra-
cranial and flank tumor establishment was confirmed by
tumor bioluminescent imaging.
Anti-GITR antibodies were dosed at 10 mg/kg in a
volume of 200 μL by intraperitoneal (i.p.) injection 10,
13, and 16 days after tumor implantation. It was con-
firmed that administration of an anti-GITR matched iso-
type control antibody led to no appreciable differences
in result when compared to the lack of antibody admin-
istration in control and SRS treatment only mice.
Radiation therapy
Focal radiation was delivered in one fraction on day 10
after tumor implantation using the small animal radi-
ation research platform [42] commercialized as SARRP
(Xstrahl). Radiation was delivered in a 3 mm vertical
beam at a rate of 1.9 Gy/min to 10 Gy centered over the
tumor with CT guidance as previously described [6].
Survival experiments and bioluminescent imaging
After intracranial implantation of 130,000 GL261-luc
cells into the left hemisphere, mice were treated with
anti-GITR mAb (10 mg/kg) and SRS (10 Gy) as de-
scribed above. Tumor burden was monitored by lucifer-
ase imaging using an IVIS Spectrum In Vivo Imager
(Caliper) as previously described [6]. Mice were sacri-
ficed according to protocol when they developed a
hunched posture or ambulatory deficits impairing feed-
ing behavior.
Flow cytometry
An LSR II (BD Biosciences) was used for flow cytometry.
The following antibodies were used: LIVE/DEAD Aqua
(Life Technologies, L34957), CD3 APC/Cy7 (BioLegend,
300317), CD3e PerCP/Cy5.5 (BD, 561108), CD4 PB
(Invitrogen, MHCD0428), CD8 BV605 (BD, 564115),
CD25 PE-Cy7 (eBioscience, 25025942), Foxp3 PE
(eBioscience, 12477182), IFN-γ PE-Cy7 (eBioscience,
25731141), TNF-α FITC (BD, 554418), IL-2 APC (BD,
562041), F4/80 PE-Cy7 (BioLegend, 123113), CD16/
CD32 APC (eBioscience, 17016181), CD16-2/FCGR4 PE
(SinoBiological, 50036R012P10), CD11b FITC (eBios-
ciences, 11011281), CD45 AF700 (BioLegend, 103127).
In vivo T cell subtype depletion
Depletion of CD4+ and CD8+ cells was achieved by i.p.
injection of 10 mg/kg of GK1.5 or 53–6.7 antibody in a
volume of 200 μL on days 5–7, 14, and 21 after tumor im-
plantation. Depletion of FoxP3+ cells in FoxP3DTR mice
was achieved by i.p. injection of 50 ng/g of diphtheria
toxin in a volume of 200 μl on day 8 and 9 after tumor im-
plantation and every 2 days thereafter until euthanasia to
maintain depletion. Depletion of >99 % of T cell subsets
was confirmed by testing peripheral blood of control mice
for the presence of CD4+, CD8+, or Foxp3+ cells using
flow cytometry.
Immunophenotyping of tumor-infiltrating lymphocytes
and myeloid cells
For intracranial tumors 130,000 GL261-luc cells were
implanted in the left hemisphere, and for flank tumors 2
million GL261-luc cells were implanted subcutaneously
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in the left flank. Mice were treated with anti-GITR anti-
body on days 10, 13, and 16 after implantation and with
SRS on day 10 after implantation. Mice with intracranial
tumors were sacrificed on day 21 post implantation and
with flank tumors were sacrificed on day 18 post im-
plantation. Tumors were excised from surrounding tis-
sue, homogenized, and infiltrating lymphocytes or
mononuclear cells were isolated using centrifugation on
a Percoll (Sigma) density gradient. For immune cell iso-
lation, a working solution of Percoll was prepared by
combining 90 % Percoll and 10 % HBSS (10×), which
was then used to produce 40 and 80 % solutions for
lymphocyte isolation and 30 and 70 % solutions for
mononuclear cell isolation. Gradients were spun for
20 min at 2000 RPM at room temperature with no
brake. The resultant cell layer was collected from the
density interface and thoroughly washed in 50 mL of
PBS. Red blood cells were lysed from harvested spleen
samples. Tumor draining lymph nodes (TDLN), consid-
ered deep cervical lymph nodes for intracranial tumors
and inguinal lymph nodes for flank tumors, were care-
fully dissected, homogenized, and washed in 1 mL of
PBS. When indicated, harvested lymphocytes from
tumor, spleen, and TDLN were stimulated with phorbal
12-myristate 13-acetate (PMA)/Ionomycin in the pres-
ence of Golgi Stop for 4 h at 37 °C. Cells were then
washed and stained for appropriate intracellular or
extracellular markers and analyzed by flow cytometry on
an LSR II (BD).
Quantitative RT-PCR
Mice were implanted intracranially with 130,000 GL261
cells in the left hemisphere, treated with anti-GITR anti-
body on days 10, 13 and 16 and with SRS on day 10 post
implantation. Mice were sacrificed on day 21 after im-
plantation. Tumors were excised, processed, and mono-
nuclear cells isolated with centrifugation on a density
gradient (Percoll). Resulting cells were washed, stained
for CD11b and CD45, and sorted for CD11b + CD45+
cells on a FACSAria II (BD) into TRIzol Reagent (Life
Technologies) to extract mRNA using the TRIzol RNA
Isolation Protocol. Cellular mRNA was quantified using
a Nanodrop 8000 UV spectrophotometer. RNA (1 μg)
was converted to cDNA using the RNA to cDNA
EcoDry Premix (Clontech). Resultant cDNA was used as
a template to target mouse IL12 (p35 subunit transcript),
IL10, Tgfb, MhcII, Cd86, Pdl1, Cd163, Cd206, Arg1, and
Inos. Primers were purchased from Life Technologies-
Applied Biosystems. An Applied Biosystems StepOne-
Plus instrument was used to amplify samples in tripli-
cate. The ΔΔCt method was used to calculate quantity
of mRNA expression relative to the average of the
control treatment group.
Statistics
Data were analyzed with log-rank test and unpaired
student’s t test on GraphPad Prism software. Signifi-
cant p-values were those less than 0.05. Experiments
were repeated x2–3.
Additional file
Additional file 1: Figure S1. Isolated CD45 + CD11b + tumor infiltrating
mononuclear cells. C57BL/6 mice were inoculated with GL261-luc tumor,
randomized to groups of ≥5, and dosed with anti-GITR (1) and SRS as in
Fig. 1. Mice were sacrificed on day 21, tumor infiltrating mononuclear
cells were isolated, cells were stained with extracellular markers and
sorted by the indicated CD45 + CD11b + gate. Numbers within boxes
indicate gated percentage of total mononuclear cell population; numbers
below boxes indicate absolute cell count of gated cells. (PDF 60 kb)
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